A medication called ibudlast is showing promise in early trials for multiple sclerosis.
Ibudilast (MN-166) has shown enough promise as a treatment for progressive multiple sclerosis (MS) that its U.S. Phase 2b trial (NCT01982942) should continue, the U.S. National Institute of Health’s Data and Safety Monitoring Board has recommended.
A key goal of the 96-week trial is to determine whether ibudilast can slow the progress of brain tissue in both secondary and primary progressive MS patients. Another goal is to determine whether it is safe for MS treatment.
Ibudilast has been approved in Japan and Korea since 1989 to treat post-stroke complications and bronchial asthma.
Half of the 255 patients enrolled in the MS-treatment trial have finished it, with 127 remaining.
Besides effectiveness and safety, the trial will look at cognitive impairment, neuropathic pain, measures of disability, patients’ quality of life, and imaging to determine how brain and eye tissue are holding up.
Read full article: MS Treatment Ibudilast Shows Enough Promise to Continue Trial
|Read Full Article: MS Treatment Ibudilast Shows Enough Promise to Continue Trial|